This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Dec. 18, 2012 /PRNewswire/ -- The areas where life sciences companies locate their facilities, commonly called industry clusters, are shifting worldwide as these companies respond to rising demand for new drugs in
Latin America, significant patent expirations and the need for increased R&D productivity and innovation. According to Jones Lang LaSalle's second annual
Global Life Sciences Cluster Report, which will be broadly distributed in
January 2013, life sciences companies are choosing cities where they can capture market opportunities for sales, drive R&D productivity and optimize operations.
With downward pricing pressure and the need to control facility costs, life sciences companies are making calculated and strategic decisions for their facilities investments. The historical dynamic of mature-market R&D discovery vs. offshoring lower-value operations is slowly evolving as emerging markets increasingly drive consumer demand.
"Major life sciences companies are optimizing their real estate and location strategies to be prepared for patent expirations – as well as to capture market opportunity in the
Asia Pacific and Latin American regions," said
Bill Barrett, Executive Managing Director, Life Sciences at Jones Lang LaSalle.
"Strategic facilities investments have become critical to keeping a tight rein on costs while continuing to find success through R&D investment and new drug discovery.'"
While every regional cluster is unique, the interplay at a global level reveals clear trends separating mature versus emerging markets. Established life sciences clusters in mature markets are being driven by R&D success and proven innovation, while the potential for significant sales growth continues to push expansion in
Asia Pacific and
Evolving Consumer Demand Drivers Focus on Emerging Markets
Rising demand in emerging markets is driving more than sales offices; manufacturing and drug development operations are thriving as well, as clusters in emerging economies strive to move up the value chain while capturing local consumer demand, particularly in the
Asia Pacific and Latin American regions.
China is expected to leapfrog ahead of
Japan and become second only to
the United States as the world's largest pharmaceuticals market. Healthcare expenditure is growing rapidly as a percentage of GDP not only in
China, but also in
India and Indonesia—countries in which increased spending on public healthcare is widening the prospective patient pool and increasing consumer demand. Four of the largest pharmaceutical companies already earn a third of their revenues outside their traditional markets of
the United States,
Western Europe and
Emerging clusters in
Asia Pacific and
Latin America have long been destinations for clinical trials, manufacturing and distribution by multinational companies, which continue to make significant facilities investments in these regions. Despite increased affluence, for example,
India continues to shine as a location for cost-effective clinical trials.
Despite the erosion of its cost advantage by rising wages and other factors,
China also remains a very cost-effective site for R&D. In
Beijing, for example, a global pharmaceutical company has launched a five-year
$1.5 billion project to build a new facility to house 600 researchers focused on drug discovery and translational research, taking advantage of nearby major universities and hospitals along with lower facilities costs than would be found in more mature markets.
Some emerging clusters are aiming higher up the value chain as R&D support destinations. Clusters in
Asia Pacific and
Latin America are aggressively increasing their competitiveness and life sciences capabilities through economic incentives, public funding, education policies and stronger intellectual property protection and international cooperation.
Singapore have been seeking to increase their presence in the industry beyond manufacturing, dedicating resources to fund intellectual capital, business parks and incubator centers while retaining a competitive cost environment for attract foreign direct investment in R&D.
"We are seeing even greater bifurcation of location strategies in response to industry stressors," said Barrett. "Multinationals are aggressively outsourcing operations to the most cost-effective locations, while focusing resources on increasing R&D productivity, either in mature clusters or in low-cost clinical trials locations."